AZ 00003

Investigator: Mahendra Jain, MD

Study Coordinator: Bela Jain

Status: Open Not Enrolling Number: NCT02229396

Phone: 281.485.3434

IRB Number: Pro00011882


Study D5553C0003 is a 28-week, randomized, double-blind, active-controlled, multicenter, Phase 3 efficacy and safety study with a 24-week extension phase of simultaneous administration of exenatide once weekly (EQW) 2 mg and dapagliflozin 10 mg once daily (QD) compared to EQW 2 mg alone and dapagliflozin 10 mg QD alone in patients with Type 2 diabetes who have inadequate glycemic control on metformin.
More to Explore